

HBV Forum 12

Tuesday, June 4, 2024

StarHotels Business Palace

Via Privata Pietro Gaggia, 3, 20139, Milan, Italy

AGENDA

12:00 PM		Registration & Lunch	
1:30 PM	Introductory Remarks and Program Overview		
1:35 PM	Welcome, Introduction, Forum Updates, Program Overview and Acknowledgements		
Session I: Updates and Setting the Stage			
Moderators: Veronica Miller, Forum for Collaborative Research and Terry Wright, GSK			
1:50 PM	Update: Towards Accelerating HBV Clinical Research in Africa	Mitchell Leus, Forum for Collaborative Research Veronica Miller, Forum for Collaborative Research	
2:00 PM	Participant Comments: Towards Accelerating HBV Clinical Research in Africa	Asgeir Johannessen, Hepatitis B in Africa Collaborative Network (HEPSANET) Mark Sonderup, University of Cape Town Wendy Spearman, University of Cape Town	
2:10 PM	EMA Proposed Update to HBV Guideline	Stephanie Buchholz*, European Medicines Agency	
2:25 PM	Open Discussion	All Meeting Participants	
Session II: Gene Editing and Epigenetic Platforms for HBV Cure			
Moderators: Jordan Feld, Toronto Center for Liver Disease and Ed Gane, University of Auckland			
2:40 PM	Academic Overview Presentation	Fabien Zoulim*, INSERM - French National Institute of Health and Medical Research	
2:50 PM	PBGENE-HBV: ARCUS gene editing to eliminate the root cause of Hepatitis B	Cassie Gorsuch*, Precision BioSciences	
3:00 PM	Epigenetic Silencing of the Viral Genome as a Therapy for Chronic Hepatitis B	Kendra Congdon, Tune Therapeutics	
3:10 PM	Regulatory Perspective	Vaishali Popat*, FDA/CBER Office of Therapeutic Products	
3:20 PM	Panel Discussion	Kendra Congdon, Tune Therapeutics Emily Harrison, Precision BioSciences Vaishali Popat*, FDA/CBER Office of Therapeutic Products Thomas Tu, Westmead Institute for Medical Research, HepBCommunity.org, Hepatitis B Voices Australia Fabien Zoulim*, INSERM - French National Institute of Health and Medical Research	

HBV Forum 12
Tuesday, June 4, 2024
StarHotels Business Palace
Via Privata Pietro Gaggia, 3, 20139, Milan, Italy

AGENDA

4:00 PM	Break	
Session III: Immune Checkpoint Inhibitors in HBV Clinical Development		
Moderators: Sue Currie, Virion Therapeutics and Adam Gehring, Toronto Center for Liver Disease		
4:30 PM	Immune Checkpoint Inhibitor (ICI) Treatment and Immune-related Adverse Events (IrAEs): Lessons Learned from Oncology for its Potential Use for Chronic Hepatitis B (CHB) Patients	Agustina Crespi*, Toronto Center for Liver Disease Mitchell Leus, Forum for Collaborative Research
4:45 PM	Patient Perspectives	Su Wang, Center for Asian Health, Cooperman Barnabas Medical Center, Global Health Advisor, Hepatitis B Foundation
4:50 PM	Open Discussion	All Meeting Participants
Session IV: HDV Assay Development Project		
Moderators: Veronica Miller, Forum for Collaborative Research and Norah Terrault, Keck Medicine at USC		
5:20 PM	Regulatory Perspective	Veronica Miller, Forum for Collaborative Research Norah Terrault, Keck Medicine at USC
5:35 PM	Panel Discussion	Maria Ines Garcia*, FDA Center for Devices and Radiological Health (CDRH) Robert Gish, Hepatitis B Foundation Scott Patterson, Gilead Sciences Christian Voitenleitner, Roche Diagnostics Heiner Wedemeyer, Hannover Medical School Kathleen Whitaker*, FDA Center for Devices and Radiological Health (CDRH)
6:00 PM	Open Discussion	All Meeting Participants
6:20 PM	Meeting Wrap Up and Adjourn	
6:30 PM	HBV, Liver and PSC Forums Networking Reception	

* Indicates remote participation

**QR Code: HBV Forum 12
Feedback Form**

